<!DOCTYPE html>
<html lang="en">
<head>
<?php $id='1975-1078'; include '../../seo.php';?>
<?php include '../../side-nav.php';?>
<div class="page-content">
<!--section-->
<div class="section mt-0">
<div class="breadcrumbs-wrap">
<div class="container">
<div class="breadcrumbs">
<a href="https://sprintdiagnostics.in/">Home</a>
<a href="https://www.sprintdiagnostics.in/hyderabad/test/">Test</a>
<span>Flow Cytometry ZAP-70 (CLL Prognostication) with CD19</span>
</div>
</div>
</div>
</div>
<!--//section-->
<!--section-->
<div class="section page-content-first">
<div class="container mt-6">
<div class="row">
<div class="col-md-8 col-lg-8 mt-0 mt-md-0 mb-4">
<h1 class="test-h1">Flow Cytometry ZAP-70 (CLL Prognostication) with CD19</h1>
<div class="post-text">
<p>ZAP-70 (Zeta-chain-associated protein kinase 70) is an enzyme that is commonly expressed in T cells and NK cells, but not in normal B cells. However, in chronic lymphocytic leukemia (CLL), the expression of ZAP-70 is associated with more aggressive disease and worse prognosis. The presence of ZAP-70 in CLL cells correlates with unmutated IgVH genes, a known adverse prognostic factor in CLL. Hence, the
assessment of ZAP-70 alongside CD19, a B cell marker, is of great clinical significance in the management of CLL patients.</p>
<div class="table-wrap">
<table class="table table-striped">
	<thead>
		<tr>
			<th scope="col">Test Name</th>
			<td scope="col">Flow Cytometry ZAP-70 (CLL Prognostication) with CD19</td>
		</tr>
	</thead>
	<tbody>
		<tr>
			<th scope="row">Sample Type</th>
			<td>Peripheral blood/Bone Marrow</td>
		</tr>
		<tr>
			<th scope="row">Preparations Required</th>
			<td>There are no specific preparations required for this test. The patient should inform the doctor about any ongoing medication or health conditions.</td>
		</tr>
		<tr>
			<th scope="row">Report Time</th>
			<td>2 days</td>
		</tr>
		<tr>
			<th scope="row">Price in Hyderabad</th>
			<td>â‚¹ 4500</td>
		</tr>
	</tbody>
</table>
</div>
<div class="post-text">
<h2 class="test-h2 mt-3">What is the Flow Cytometry ZAP-70 (CLL Prognostication) with CD19 test?</h2>
<p>The Flow Cytometry ZAP-70 (CLL Prognostication) with CD19 is a diagnostic procedure that measures the expression of ZAP-70 in CD19 positive cells (B-cells) to predict disease progression and survival outcomes in patients with Chronic Lymphocytic Leukemia (CLL).</p>

<h2 class="test-h2 mt-3">Why is this test performed?</h2>
<p>This test is performed to evaluate the prognosis of patients with CLL. A higher expression of ZAP-70 in B-cells is associated with a more aggressive disease course and a poorer prognosis.</p>

<!--section achieved-->
<?php include "../../include/iconsbox.php" ?>
<!--//section achieved-->

<h2 class="test-h2 mt-3">How is the test performed?</h2>
<p>The test requires a sample of the patient&#39;s peripheral blood or bone marrow, which is then subjected to flow cytometry. In this technique, the cells are tagged with fluorescent-labeled antibodies specific for ZAP-70 and CD19. These labeled cells are then passed through a laser beam, causing them to fluoresce. The fluorescent intensity is then measured and analyzed, providing the percentage of ZAP-70 positive B- cells.</p>

<h2 class="test-h2 mt-3">What do the test results mean?</h2>
<p>High levels of ZAP-70 in B-cells suggest a higher likelihood of disease progression and a poorer prognosis. Conversely, low levels of ZAP-70 are associated with slower disease progression and a better prognosis.</p>

<h2 class="test-h2 mt-3">Is there any preparation needed for this test?</h2>
<p>No special preparation is required for this test. However, the patient should always inform the doctor about any ongoing medications or health conditions.</p>


<h2 class="test-h2 mt-3">How often should this test be done?</h2>
<p>The frequency of this test is determined by the doctor, typically guided by the patient&#39;s response to treatment, the stage of the disease, and the patient&#39;s overall health.</p>

<h2 class="test-h2 mt-3">What factors can affect the test results?</h2>
<p>Factors that can influence the test results include the timing and quality of the sample collection, the patient&#39;s overall health, and the stage of the disease.</p>

<h2 class="test-h2 mt-3">Who should I consult if my test results are abnormal?</h2>
<p>If the test results are abnormal, the patient should consult a hematologist or an oncologist specializing in leukemia.</p>

<h2 class="test-h2 mt-3">Are there any risks associated with this test?</h2>
<p>The risks associated with this test are minor and relate to the collection of the blood or bone marrow sample. These may include slight pain, light-headedness, or minor bleeding at the puncture site.</p>

<h2 class="test-h2 mt-3">What does an abnormal result mean?</h2>
<p>An abnormal result, i.e., high levels of ZAP-70 in B-cells, suggests a higher likelihood of disease progression and a poorer prognosis.</p>

<h2 class="test-h2 mt-3">What treatment options are available for patients with CLL?</h2>
<p>The treatment for CLL depends on several factors, including the stage of the disease, the patient&#39;s overall health, the presence of certain genetic changes, and the patient&#39;s symptoms. Treatment options can range from a &quot;watch and wait&quot; approach to  therapies such as chemotherapy, immunotherapy,
targeted therapies, and stem cell transplantation.</p>

<h2 class="test-h2 mt-3">How does the ZAP-70 test contribute to CLL management?</h2>
<p>The ZAP-70 test plays a vital role in predicting disease progression and survival in patients with CLL, thus assisting in risk stratification and guiding therapy decisions.</p>

<p>Flow cytometry is a crucial tool for diagnosing and monitoring hematological malignancies, including CLL. In recent years, studies have focused on identifying and validating new biomarkers to improve the prognostic accuracy and guide therapeutic decisions. The combination of flow cytometry with next- generation sequencing technologies promises even more comprehensive profiling of CLL, further improving patient care.</p>

<p>Flow cytometry ZAP-70 (CLL prognostication) with CD19 is a vital test that helps in risk stratification of CLL patients, guiding treatment decisions. By identifying patients with a more aggressive disease course, appropriate therapeutic interventions can be initiated promptly, thus improving patient outcomes. It is essential that patients discuss the implications of this test with their healthcare provider to understand its relevance in the context of their overall disease management.</p>

</div>		
</div>			
</div>
<!--form section-->
<?php include "../../include/bookslot.php" ?>
<!--form section-->
</div>
</div>
<!--//section-->
</div>
</div>
<?php include '../../footer.php';?>
</body>
</html>